These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29958128)

  • 1. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
    Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
    Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
    Alford DP; LaBelle CT; Kretsch N; Bergeron A; Winter M; Botticelli M; Samet JH
    Arch Intern Med; 2011 Mar; 171(5):425-31. PubMed ID: 21403039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.
    Roll D; Spottswood M; Huang H
    J Am Board Fam Med; 2015; 28(5):676-7. PubMed ID: 26355141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
    Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC
    Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten Years of Experience With Buprenorphine in a Private Psychiatric Outpatient Practice.
    Feder R
    Am J Addict; 2020 Nov; 29(6):508-514. PubMed ID: 32410327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.
    Stein MD; Conti MT; Herman DS; Anderson BJ; Bailey GL; Noppen DV; Abrantes AM
    Am J Addict; 2019 Jul; 28(4):270-276. PubMed ID: 30993833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
    Williams AR; Samples H; Crystal S; Olfson M
    Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.